These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630 [TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia: 2013 update on risk-stratification and management. Estey EH Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416 [TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia. Stone RM; O'Donnell MR; Sekeres MA Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. Komanduri KV; Levine RL Annu Rev Med; 2016; 67():59-72. PubMed ID: 26473413 [TBL] [Abstract][Full Text] [Related]
8. Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia. Jeziskova I; Semerad L; Dvorakova D; Janeckova V; Culen M; Kunetkova T; Mayer J; Racil Z Leuk Lymphoma; 2017 Mar; 58(3):746-748. PubMed ID: 27484360 [No Abstract] [Full Text] [Related]
9. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612 [TBL] [Abstract][Full Text] [Related]
10. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation? Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098 [TBL] [Abstract][Full Text] [Related]
11. Research on the clinical effect and in vitro study of HLA-mismatched hematopoietic stem cell infusion for acute myeloid leukemia. Zhang R; Zhao F; Wang J Hematology; 2015 Dec; 20(10):555-60. PubMed ID: 26067370 [TBL] [Abstract][Full Text] [Related]
12. Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia. Orozco JJ; Appelbaum FR Oncology (Williston Park); 2012 Aug; 26(8):706-12. PubMed ID: 22957403 [TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. Jackson K; Kennedy G; Mollee P; Marlton P; Morris K Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype. Zidan MA; Kamal Shaaban HM; Elghannam DM Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521 [TBL] [Abstract][Full Text] [Related]
16. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Schlenk RF; Döhner K Curr Opin Hematol; 2009 Mar; 16(2):98-104. PubMed ID: 19468271 [TBL] [Abstract][Full Text] [Related]
17. Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. Bernardi M; Carrabba M; Messina C; Milani R; Sala E; Pavesi F; Gentner B; Peccatori J; Assanelli A; Marktel S; Corti C; Forcina A; Vago L; Ciceri F Am J Hematol; 2016 Jun; 91(6):E302-3. PubMed ID: 26928240 [No Abstract] [Full Text] [Related]
18. Acute myeloid leukemia. Rubnitz JE; Gibson B; Smith FO Pediatr Clin North Am; 2008 Feb; 55(1):21-51, ix. PubMed ID: 18242314 [TBL] [Abstract][Full Text] [Related]
19. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872 [TBL] [Abstract][Full Text] [Related]
20. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]